Gene study reveals why some lymphoma patients clear chemo slower
NCT ID NCT06031194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined how genetic variations influence the body's ability to clear high-dose methotrexate in 20 adults with diffuse large B-cell lymphoma or central nervous system lymphoma. Researchers looked for specific gene changes linked to slower drug removal. The goal was to better understand drug metabolism, not to provide a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?